Changes

HAEM5:Volunteer Assignments and Opportunities (view source)

Revision as of 11:26, 23 December 2023

316 bytes added , 11:26, 23 December 2023

no edit summary

Line 1,776: Line 1,776:

|

|-

−

|Primary large B-cell lymphoma of immune-privileged sites||Disease|| || || || || ||GC|| ||

+

|[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease|| || || || || ||GC|| ||

|

|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center

Line 1,783: Line 1,783:

|

|-

−

|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| ||

+

|[[HAEM5:Primary cutaneous diffuse large B-cell lymphoma, leg type|Primary cutaneous diffuse large B-cell lymphoma, leg type]]||Disease|| || || || || ||GC|| ||

|

Line 1,790: Line 1,790:

|

|-

−

|Intravascular large B-cell lymphoma||Disease|| || || || || ||GC|| ||

+

|[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||

|

|Kate Berry, MBBS, BBus (Hons), Pathology Queensland

Line 1,797: Line 1,797:

|

|-

−

|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| ||

+

|[[HAEM5:Primary mediastinal large B-cell lymphoma|Primary mediastinal large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||

|

Line 1,804: Line 1,804:

|

|-

−

|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| ||

+

|[[HAEM5:Mediastinal grey zone lymphoma|Mediastinal grey zone lymphoma]]||Disease|| || || || || ||GC|| ||

|

Line 1,811: Line 1,811:

|

|-

−

|High-grade B-cell lymphoma, NOS||Disease|| || || || || ||GC|| ||

+

|[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease|| || || || || ||GC|| ||

|

|Aiko Otsubo, PhD, Indiana University

Jennelleh

Bureaucrats, Editors, Administrators

3,881

edits